Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Chemotherapy as Neoadjuvant Therapy for Early-Stage Oral Squamous Cell Carcinoma
NCT07827872Phase 3Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2032
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in oral squamous cell carcinoma (OSCC). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07827872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827872.